This is the authors' abstract. We don't add key points for this paper.
Hematopoietic stem cell transplant (HSCT) has emerged during the past 6 decades as an increasingly successful option to cure a variety of malignant and nonmalignant disorders in children. HSCT has been performed in humans since the late 1950s, with significant success first noted in the 1970s. At that time, indications for transplant began to expand beyond malignancies and some bone marrow failure disorders: the scope of pediatric diseases treatable by HSCT now includes, in addition to malignant disorders such as high-risk acute leukemias and solid tumors, a wide range of hereditary conditions, including storage and metabolic disorders, hemoglobinopathies, and immune deficiencies (Table).Posttransplant survival in pediatric patients has continuously improved over time from a combination of refined approaches to patient selection, conditioning, and improved supportive care. For example, 5-year survival after a matched sibling donor transplant for pediatric acute lymphoblastic leukemia is now 70%, a remarkable achievement over only a few decades of experience.Improvements in HSCT outcomes are not limited to the care of children with malignancies; they are noted across the breadth of indications for the procedure. For example, newborn screening programs now identify babies with X-linked adrenoleukodystrophy or severe combined immunodeficiency, enabling rapid referrals for HSCT before the onset of symptoms. Performing HSCT urgently in such patients has led to durable cures with excellent long-term outcomes before patients develop sequelae of their hereditary diseases.In patients with hematologic malignancy, the indications for transplant have evolved over time, as survival rates with chemotherapy alone have risen and the ability to stratify patients into risk categories has improved with advanced molecular diagnostic tools. Overall survival for pediatric acute lymphoblastic leukemia (ALL), for example, is greater than 90%, and recent clinical trials aim to maintain excellent outcomes while decreasing exposure to chemotherapy and its adverse effects. Most transplants for ALL are, thus, performed in children who are unlikely to achieve a durable cure from chemotherapy alone, such as those for whom remission is difficult to achieve or who relapse during or soon after treatment. For pediatric patients with acute myeloid leukemia, the decision to proceed to HSCT is based predominantly on risk stratification using cytogenetic and molecular features of the leukemia.HSCT approaches and outcomes vary greatly for heritable conditions such as sickle cell anemia, thalassemias, storage disorders, leukodystrophies, bone marrow failure syndromes, and immunodeficiencies. For most transplant indications, overall success is greatest with matched sibling donors. When a matched sibling donor is unavailable, outcomes with alternative donors vary by disease type. For some conditions, such as severe combined immunodeficiency or X-linked adrenoleukodystrophy with active neurologic decline, proceeding to HSCT urgently is of critical importance. For others, proceeding to HSCT is not urgent but outcomes are more favorable in younger patients. Generally, performing HSCT in a patient before the underlying heritable condition has led to an accumulation of irreversible organ damage is desirable, most notably in sickle cell disease, where the safety of transplant decreases markedly after the first or second decade.The degree of risk a child incurs from HSCT is determined largely by the type of transplant and the type of donor chosen, as well as pre-HSCT comorbidities. Allogeneic (allo) transplants, in which donor cells are from a second party, are riskier than autologous (auto) transplants, in which the patient’s own stem cells are collected in advance and infused back into the patient at a later date. With allo-HSCT, the new (donor) immune system recognizes every organ in the recipient’s body as foreign, creating the risk of graft-versus-host disease (GvHD), which is usually morbid and may be fatal. Furthermore, the intensity of immunosuppression used to either prevent or treat GvHD may lead to numerous complications, including increased and prolonged risk of opportunistic infections. Another consideration is that not all allotransplants are equal in the risks they pose: unrelated or unmatched donors portend a markedly higher risk of GvHD and mortality than do related and fully matched donors.The expected timeline of recovery from HSCT also varies with the type of transplant. A child receiving an auto-HSCT is expected to recover within several weeks and have no risk of GvHD, whereas a child receiving an unrelated donor allo-HSCT is expected to have many months of profound immunosuppression in an effort to prevent and/or treat GvHD. Typically, for allo-HSCT the patient recuperates for several weeks as an inpatient, followed by months of frequent outpatient clinic visits that are spaced gradually from multiple times a week to less frequent visits as the need for transfusions, medication infusions, and monitoring for complications decreases. The timeline for frequent visits is significantly lengthened whenever therapies intensify, as in the case of GvHD or reactivation of previous viral infections. During this intensive period of outpatient management, patients continue to be at significant risk for viral, bacterial, and fungal infections; restrictions are thus imposed on all aspects of their lives, including socializing in crowded spaces, school, diet, and contact with animals. Generally, patients are not referred back to their primary care provider for several months after transplant, depending on how many complications they incur that require ongoing transplant follow-up, although ongoing communication with the primary care provider during this time promotes continuity of care.In the long-term, patients continue to need intermittent evaluations by the transplant team to evaluate for development of chronic GvHD, organ damage from therapies given, disease relapse in the case of transplant for malignancy, and secondary malignancy. Long-term follow-up for posttransplant patients includes monitoring for relapse/secondary cancers, endocrinopathies, heart and lung toxicity, bone and growth abnormalities, kidney damage, and psychological as well as cognitive effects. In addition, fertility may be impaired, and fertility preservation techniques may or may not have been possible or desired depending on the age of the child at transplant, the underlying disease process, and the resources available.The psychological and emotional stressors endured by pediatric transplant patients and their families and caregivers is a critically important consideration. The isolation that a child and caregivers experience from spending weeks or months in a solitary hospital room is significant. The loneliness and isolation are further compounded by the lack of returning to normal life after hospital discharge. With restrictions on social interactions continuing for many months after transplant, families often find that their lives are significantly altered by the dissolution or at least alteration of their broader support network. The loss of friends, school routines, academic engagement, and major childhood life milestones may have profound psychological, developmental, and emotional consequences. At a minimum, cognitive performance may be affected by being out of school for such a long time and should be monitored with neuropsychological testing.Other family members are also affected by the transplant experience. Siblings may experience isolation, loneliness, or loss of control, with the patient occupying a significant proportion of the parents’ time and attention. In particular, the psychological well-being of sibling stem cell donors must be considered, especially when the patient experiences a poor outcome.Despite the hardships endured in pediatric HSCT, the future is bright as increasing numbers of children benefit from this therapy each year, achieving cures and survival rates previously unattainable. The search for less toxic alternatives to HSCT is well underway, with advances in conditioning regimens, novel graft manipulation techniques such as selective T-cell depletion, early screening and interventions, and genetic and cellular therapies such as chimeric antigen receptor T cells (CAR-T cells). In the coming decades, more children will benefit from such disease-altering and lifesaving therapies. General pediatricians can, therefore, expect to care for an increased number of HSCT or cellular therapy survivors in their practices.Comments: For those of us who thought that the coming of stem cell transplant was taking us to a brave new world, what can we say about the recent emergence of gene enhancement therapies, such as nusinersen for spinal muscular atrophy and cellular therapies typified by CAR-T cells? Both the technology and, even more, the visionary imagination underpinning these new developments are breathtaking.Spinal muscular atrophy results from deletion or loss-of-function mutations in the SMN1 gene, which codes for the survival motor neuron protein. The SMN1 gene has a brother gene, SMN2, which is less effective at producing the SMN protein. Nusinersen is an antisense oligonucleotide that essentially converts the SMN2 gene into a functional SMN1 gene, producing enough protein to maintain motor neuron function. Importantly, its method may well serve as a model for treating other neurodegenerative disorders.CAR-T cells are at the forefront of immunotherapy in which a patient’s own T cells are engineered to develop CARs. These CARs enable the T cells to recognize and attach to a specific antigen on the patient’s cancer cells, which can then be killed. To date, CAR–T-cell therapy has been successful in treating ALL and lymphomas that have not responded to more traditional therapeutic modalities.Brave new world indeed!
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fraint et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: